Table 3.
Additional irAEs in the Princess Margaret Cancer Centre cohort.
| Immune-Related Adverse Events | All Grades a | G1 | G2 | G3 | G4 |
|---|---|---|---|---|---|
| AST increased | 7 | 6 | 0 | 1 | 0 |
| ALT increased | 8 | 5 | 3 | 0 | 0 |
| Troponin increased | 1 | 1 | 0 | 0 | 0 |
| CPK increased | 1 | 0 | 0 | 0 | 1 |
| Pancreatic enzymes decreased | 1 | 0 | 1 | 0 | 0 |
| Amylase increased | 1 | 0 | 1 | 0 | 0 |
| Lipase increased | 1 | 0 | 0 | 1 | 0 |
| Hypothyroidism | 6 | 0 | 6 | 0 | 0 |
| Hyperthyroidism | 3 | 2 | 1 | 0 | 0 |
| Diarrhea | 2 | 0 | 1 | 1 | 0 |
| Colitis | 2 | 0 | 2 | 0 | 0 |
| Rash | 3 | 1 | 2 | 0 | 0 |
| Pruritus | 1 | 1 | 0 | 0 | 0 |
| Vitiligo-like skin depigmentation | 2 | 0 | 2 | 0 | 0 |
| Hyperkeratosis | 1 | 0 | 0 | 1 | 0 |
| Guillain–Barré syndrome | 1 | 0 | 1 | 0 | 0 |
| Total | 41 | 16 | 20 | 4 | 1 |
a: Grades according to the Common Terminology Criteria for Adverse Events, version 5.0. ALT: alanine aminotransferase; AST: aspartate aminotransferase; CPK: creatine phosphokinase; irAEs: immune-related adverse events.